PRODUCT INFORMATION
LATANOPROST / TIMOLOL SANDOZ® 50/5 Eye Drops

NAME OF THE MEDICINE
Latanoprost/Timolol Sandoz 50/5 is a combination eye drop containing latanoprost and timolol maleate.

Latanoprost
Chemical name: Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl]-5-heptenoate.

![Latanoprost Structure](image)

The CAS number for Latanoprost is 130209-82-4
Empirical formula: $\text{C}_{26}\text{H}_{40}\text{O}_5$  
MW: 432.59

Timolol maleate
Chemical name: (S)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt).

![Timolol Maleate Structure](image)

The CAS number for timolol maleate is 26921-17-5.
Empirical formula: $\text{C}_{13}\text{H}_{24}\text{N}_4\text{O}_5\text{S} \cdot \text{C}_4\text{H}_4\text{O}_4$  
MW: 432.49
DESCRIPTION
Latanoprost/Timolol Sandoz 50/5 Eye Drops is a sterile solution containing 50 micrograms/mL of latanoprost and 5 mg/mL of timolol (6.83 mg timolol maleate) in an aqueous buffer solution pH 6.0.

Latanoprost is a prostaglandin F\textsubscript{2\alpha} analogue. Sixty four isomers of latanoprost are possible however it is purified as a single isomer. Latanoprost is a colourless to pale yellowish viscous oil. Latanoprost is practically insoluble in water, freely soluble in ethanol, ethyl acetate, isopropanol, methanol, acetone, octanol and is very soluble in acetonitrile.

Timolol maleate is a beta-adrenergic receptor blocking agent. Timolol maleate is a white or almost white, crystalline powder. It is freely soluble in water and ethanol, sparingly soluble in chloroform, very slightly soluble in cyclohexane and insoluble in isooctane and ether.

The excipients in Latanoprost/Timolol Sandoz 50/5 Eye Drops are benzalkonium chloride (0.2 mg/mL) as a preservative, dibasic anhydrous sodium phosphate, monobasic dihydrate sodium phosphate, sodium chloride and water for injections.

PHARMACOLOGY
Pharmacodynamics
Latanoprost and timolol eye drops consists of two components: latanoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by different mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone.

Latanoprost
Latanoprost is a selective prostanoid F\textsubscript{2\alpha} receptor agonist which reduces IOP by increasing the outflow of aqueous humour. The main mechanism of action is increased uveoscleral outflow. In addition, some increase in outflow facility (decrease in trabecular outflow resistance) has been reported in man. Latanoprost has no significant effect on the production of aqueous humour or the blood-aqueous barrier. Latanoprost has no or negligible effects on the intraocular blood circulation when used at the human clinical dose, as studied in monkeys. However, mild to moderate conjunctival or episcleral hyperaemia may occur during topical treatment.

Chronic treatment with latanoprost in monkey eyes which had undergone extracapsular lens extraction did not affect the retinal blood vessels as determined by fluorescein angiography. Latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes during short term treatment. Latanoprost in clinical doses has not been found to have any significant pharmacologic effects on the cardiovascular or respiratory systems.

Timolol
Timolol maleate is a beta\textsubscript{1} and beta\textsubscript{2} (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane-stabilising) activity. Timolol lowers IOP by decreasing the formation of aqueous humour in the ciliary epithelium. The precise mechanism of action is not clearly established.
**Latanoprost and timolol eye drops**

Onset of action of latanoprost and timolol eye drops is within one hour and maximal effect occurs within six to eight hours. Adequate IOP reducing effect has been shown to be present up to 24 hours post dosage after multiple treatments.

**Pharmacokinetics**

**Latanoprost**

Latanoprost is an isopropyl ester prodrug which is inactive, but after hydrolysis by esterases in the cornea to the acid of latanoprost, becomes biologically active.

**Absorption**

The prodrug is well absorbed through the cornea and all drug that enters the aqueous humour is hydrolysed during the passage through the cornea.

**Distribution**

Studies in man indicate that the peak concentration in the aqueous humour, approximately 30ng/mL, is reached about two hours after topical administration of latanoprost alone. After topical application in monkeys, latanoprost is distributed primarily in the anterior segment, the conjunctivae and the eye lids. Only minute quantities of the drug reach the posterior segment.

Reduction of the intraocular pressure in man starts about three to four hours after administration of latanoprost alone and maximum effect is reached after 8 to 12 hours. Pressure reduction is maintained for at least 24 hours.

**Metabolism**

The acid of latanoprost has a plasma clearance of 0.40 L/h*kg and a small volume of distribution, 0.16 L/kg, resulting in a rapid half-life in plasma, 17 minutes. After topical ocular administration, the systemic bioavailability of the acid of latanoprost is 45%. The acid of latanoprost has a plasma protein binding of 87%. There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver.

**Excretion**

The main metabolites, the 1,2-dinor and 1, 2, 3, 4-tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine.

**Timolol**

The maximum concentration of timolol in the aqueous humour is reached about 1 hour after topical administration of eye drops. Part of the dose is absorbed systemically and a maximum plasma concentration of 1 ng/mL is reached 10-20 minutes after topical administration of one eye drop to each eye once daily (300 μg/day). The half-life of timolol in plasma is about 6 hours. Timolol is extensively metabolised in the liver. The metabolites are excreted in urine together with some unchanged timolol.

**Latanoprost and timolol eye drops**

No pharmacokinetic interactions between latanoprost and timolol have been observed, although the aqueous humour concentrations of the acid of latanoprost tended to be higher, 1 to 4 hours after administration of the combination product compared to monotherapy with either agent.
CLINICAL TRIALS
Two 6-month, randomised, double-blind, multicentre clinical studies were conducted to compare the IOP-lowering effect of latanoprost and timolol eye drops dosed once daily to latanoprost 0.005% dosed once daily and timolol 0.5% dosed twice daily.

The inclusion criteria for patients in both studies consisted of adults with diagnoses of primary open angle glaucoma, pigmentary glaucoma, capsular glaucoma or ocular hypertension. Patients previously on IOP reducing therapy required an IOP at enrolment of ≥ 25 mmHg. Patients not previously on IOP reducing therapy required an IOP of ≥ 30 mmHg on enrolment. In the two studies, 92% and 84% of patients were reported to have been on IOP reducing therapy within 3 months prior to study start. Approximately 70% of these patients were on timolol therapy.

The mean diurnal IOP-lowering effect of latanoprost and timolol eye drops was greater (1 to 3 mmHg) than that produced by monotherapy with either latanoprost 0.005% or timolol 0.5%. However, there are no data to show the optimal dose of these agents in combination.

Open label extensions of the 2 studies mentioned above were conducted for up to an additional 6 months. The IOP lowering effect of latanoprost and timolol eye drops was maintained during this period.

INDICATIONS
Reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. Latanoprost/Timolol Eye drops should not be used to initiate therapy.

CONTRAINDICATIONS
Latanoprost/Timolol Sandoz 50/5 Eye Drops is contraindicated in the following:
• Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease
• Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
• Known hypersensitivity to latanoprost, timolol maleate or to any component in Latanoprost/Timolol Sandoz 50/5 Eye Drops.

PRECAUTIONS
Systemic effects
Like other topically applied ophthalmic agents, latanoprost and timolol eye drops are absorbed systemically. Incidence of systemic adverse reactions after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see DOSAGE AND ADMINISTRATION.
Cardiovascular/Respiratory reactions
Due to the beta-adrenergic component timolol, the same types of adverse reactions seen with systemic beta-blockers may occur including aggravation of Prinzmetal’s angina, aggravation of severe peripheral and central circulatory disorders, bradycardia and hypotension. In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension therapy with beta-blockers, should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.

Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and death associated with cardiac failure have been reported following administration of timolol. Cardiac failure should be adequately controlled before treatment. Patients with a history of severe cardiac disease should be monitored closely for signs of cardiac failure.

Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.

Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.

Timolol maleate should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.

A gradual withdrawal of beta-adrenergic blocking agents prior to major surgery may be considered. Beta-adrenergic blocking agents impair the ability of the heart to respond to beta-adrenergically mediated reflex stimuli, which may augment the risk of general anaesthesia in surgical procedures. Protracted severe hypotension during anaesthesia and difficulty restarting and maintaining the heartbeat, have been reported. During surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.

Anaphylactic reactions
While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

Concomitant therapy
Timolol may interact with other drugs (see also INTERACTIONS WITH OTHER MEDICINES).

The effect on intraocular pressure or the known effects of systemic beta–blockade may be exaggerated when latanoprost and timolol eye drops is given to patients already receiving an oral beta-blocking agent. The response of these patients should be closely observed. There have been reports of paradoxical elevations in IOP following the concomitant ophthalmic
administration of two prostaglandin analogues. Therefore, the use of two or more local beta-blockers or two or more local prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended.

**Additional effects of beta-blockade**

Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycaemic agents. Beta-blockers may increase the hypoglycaemic effect of agents used to treat diabetes and may mask the signs and symptoms of acute hypoglycaemia.

Therapy with beta-blockers may mask certain signs and symptoms of hyperthyroidism and abrupt withdrawal of therapy may precipitate a worsening of symptoms.

Therapy with beta-blockers may aggravate symptoms of myasthenia gravis.

**Ocular effects**

Latanoprost may gradually change the eye colour by increasing the amount of brown pigment in the iris. This effect has predominantly been seen in patients with mixed coloured irides, i.e. green-brown, yellow-brown or blue/grey-brown, and is due to increased melanin content in the stromal melanocytes of the iris. Typically the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. In patients with homogenously blue, grey, green or brown eyes, the change has only rarely been seen during two years of treatment in clinical trials with latanoprost.

The change in iris colour occurs slowly and may not be noticeable for several months to years and it has not been associated with any symptom or pathological changes.

No further increase in brown iris pigment has been observed after discontinuation of treatment, but the resultant colour change may be permanent.

Neither naevi nor freckles of the iris have been affected by treatment.

Accumulation of pigment in the trabecular meshwork or elsewhere in the anterior chamber has not been observed but patients should be examined regularly and, depending on the clinical situation, treatment may be stopped if increased iris pigmentation ensues.

Before treatment is instituted patients should be informed of the possibility of a change in eye colour. Unilateral treatment can result in permanent heterochromia.

Eyelid skin darkening, which may be reversible, has been reported in association with the use of latanoprost.

Latanoprost may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, and number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are reversible upon discontinuation of treatment.
There is no or limited experience with latanoprost or latanoprost-timolol in inflammatory, neovascular, chronic angle closure or congenital glaucoma, in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma. Latanoprost has no or little effect on the pupil but there is no experience in acute attacks of closed angle glaucoma. Therefore it is recommended that latanoprost and timolol eye drops should be used with caution in these conditions until more experience is obtained.

Latanoprost should be used with caution in patients with a history of herpetic keratitis, and should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.

Macular oedema, including cystoid macular oedema, has been reported during treatment with latanoprost. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema. Latanoprost and timolol eye drops should be used with caution in these patients.

Choroidal detachment after filtration procedures has been reported with the administration of ocular hypotensive agents.

Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.

**Use of contact lenses**
Latanoprost and timolol eye drops contains benzalkonium chloride which may be absorbed by contact lenses. Several contact lens soaking solutions contain thiomersal which may also form a precipitate with the benzalkonium chloride (see INTERACTIONS WITH OTHER MEDICINES). Therefore contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 minutes.

**Animal toxicity**
No adverse ocular or systemic effects were seen in rabbits treated topically with fixed combinations of latanoprost and timolol maleate for up to 52 weeks or with concomitantly administered latanoprost and timolol ophthalmic solutions for 4 weeks.

In long-term ocular toxicity studies in monkeys, latanoprost has been shown to induce increased iris pigmentation. The pigmentation did not progress upon discontinuation of treatment. The results from pre-clinical studies have demonstrated that the primary mechanism of increased pigmentation is stimulation of melanin production in melanocytes of the iris stroma. There is no evidence of melanocyte proliferation.

Long-term ocular administration of latanoprost at a dose of 6 μg/eye/day (4 times the daily human dose) to cynomologus monkeys has also been shown to induce an increase or widening in the palpebral fissure. This effect was reversible upon discontinuation of the drug.

Timolol maleate did not produce any adverse ocular effects in rabbits and dogs, when administered as multiple daily topical doses for up to 52 and 104 weeks, respectively.
Effects on Fertility
Fertility studies with latanoprost and timolol eye drops have not been conducted. Latanoprost or timolol maleate alone had no effects on male or female fertility in rats when administered at 250 μg/kg/day intravenously (IV) or 300 mg/kg/day orally (PO) respectively.

Use in pregnancy
Category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

Embryofetal development studies with latanoprost have been performed in rats and rabbits. Latanoprost and/or its metabolites cross the placenta of rats. In rabbits, latanoprost caused embryofetal toxicity characterised by increased incidences of late resorption and reduced fetal weight at 5 μg/kg/day IV and total litter resorption at ≥ 50 μg/kg/day IV. No embryofetal effects were seen in rabbits at 1 μg/kg/day IV and in rats at up to 250 μg/kg/day IV.

Timolol maleate was not teratogenic in mice, rats and rabbits. Embryofetal development studies with timolol maleate in mice and rabbits showed no evidence of embryofetal toxicity at oral doses up to 50 mg/kg/day. At higher doses, increases in resorptions and fetal variations (14 ribs and hypoplastic sternebrae) were noted in mice (1000 mg/kg/day) and increased resorption in rabbits (≥ 90 mg/kg/day). In rats, delayed ossification was seen at ≥ 50 mg/kg/day and a decreased number of caudal vertebral bodies and arches and an increase in hypoplastic sternebrae were noted at 500 mg/kg/day.

There are no adequate and well-controlled studies in pregnant women. Therefore, latanoprost and timolol eye drops should not be used during pregnancy.

Use in lactation
There are limited experimental animal and no human data available on the pharmacokinetics of latanoprost in lactation. Latanoprost and its metabolites may pass into breast milk.

Timolol maleate has been detected in human milk following oral and ocular administration. Because of the potential for serious adverse reactions from latanoprost and timolol eye drops in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Paediatric Use
Latanoprost and timolol eye drops is not recommended for use in children. Safety and effectiveness in children have not been established.

Genotoxicity
Mutagenicity studies with latanoprost and timolol eye drops have not been conducted.

Latanoprost was not mutagenic in gene mutation assays in bacteria and mouse lymphoma L5178Y cells and was negative in studies of unscheduled DNA synthesis. Chromosome aberrations were observed with human lymphocytes in vitro but latanoprost did not induce micronucleus formation in vivo.

In vitro and in vivo studies with timolol maleate did not reveal a mutagenic potential.
Carcinogenicity
Carcinogenicity studies with latanoprost and timolol eye drops have not been conducted.

Latanoprost was not carcinogenic in either rats or mice when administered by oral gavage at doses up to 170 μg/kg/day for 24 and 20 months respectively.

No evidence of carcinogenicity was observed with timolol maleate at oral doses up to 100 mg/kg/day in rats and 50 mg/kg/day in mice. However, there was a statistically significant increase in the incidence of adrenal phaeochromocytomas in male rats administered 300 mg/kg/day. In female mice, statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary carcinomas were found at 500 mg/kg/day. The increased incidence of mammary tumours was considered to be attributed to a species specific elevation in serum prolactin.

Effects on ability to drive and use of machines
In common with other eye preparations, instillation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines.

INTERACTIONS WITH OTHER MEDICINES
No specific interaction studies have been performed with latanoprost and timolol eye drops.

There have been reports of paradoxical elevations in intraocular pressure following the concomitant ophthalmic administration of two prostaglandin analogues. Therefore, the use of two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended.

The potential exists for additive effects resulting in hypotension, and/or marked bradycardia when timolol ophthalmic drops are administered with oral calcium channel blockers, catecholamine-depleting drugs or beta-adrenergic blocking agents, antiarrhythmics (including amiodarone and quinidine), digitalis glycosides, parasympathomimetics, narcotics and monoamine oxidase (MAO) inhibitors.

The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.

Potentiated systemic beta blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.

The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when latanoprost/timolol is given to patients already receiving an oral beta-adrenergic blocking agent, and the use of two or more topical beta-adrenergic blocking agents is not recommended.

Although latanoprost and timolol eye drops alone has little or no effect on pupil size, mydriasis has occasionally been reported when timolol is given with adrenaline.
Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents. Beta-blockers can mask the signs and symptoms of hypoglycaemia (see PRECAUTIONS – Additional effects of beta-blockade).

*In vitro* studies have shown that precipitation occurs when eye drops containing thiomersal are mixed with benzalkonium chloride, the preservative used in Latanoprost/Timolol Sandoz 50/5 Eye Drops. If such drugs are used, they should be administered with an interval of at least five (5) minutes between applications. Similarly several contact lens soaking solutions contain thiomersal (see PRECAUTIONS – Use of contact lenses).

**ADVERSE EFFECTS**

No adverse events specific for latanoprost and timolol drops have been observed in clinical studies. The adverse events have been limited to those earlier reported for latanoprost and timolol. For latanoprost, the majority of adverse events relate to the ocular system. For timolol, the most serious adverse events are systemic in nature, including bradycardia, arrhythmia, congestive heart failure, bronchospasm and allergic reactions.

Like other topically applied ophthalmic medicinal products, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta blocking agents. Incidence of systemic adverse drug effects after topical ophthalmic administration is lower than for systemic administration. Listed adverse effects include reactions seen within the class of ophthalmic beta-blockers.

**Adverse events from clinical trials**

Adverse events occurring at a frequency of ≥ 1% in three randomised, double blind comparative trials (004, 005 and 053) are presented in Tables 1 and 2.

**Table 1**

Ocular adverse events (AE) that occurred in ≥ 1% of patients*, in any treatment group, by preferred term†

<table>
<thead>
<tr>
<th>Body system / preferred term</th>
<th>Number (%) of patients per treatment group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Latanoprost/Timolol Timolol</td>
</tr>
<tr>
<td></td>
<td>N=394</td>
</tr>
<tr>
<td><strong>Vision</strong></td>
<td></td>
</tr>
<tr>
<td>Blepharitis</td>
<td>10 (2.5)</td>
</tr>
<tr>
<td>Cataract</td>
<td>11 (2.8)</td>
</tr>
<tr>
<td>Conjunctival disorder</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>12 (3.0)</td>
</tr>
<tr>
<td>Corneal disorder</td>
<td>12 (3.0)</td>
</tr>
<tr>
<td>Corneal ulceration</td>
<td>1 (0.3)*</td>
</tr>
<tr>
<td>Cystoid macular oedema</td>
<td>1 (0.3)*</td>
</tr>
<tr>
<td>Epiphora</td>
<td>3 (0.8)</td>
</tr>
<tr>
<td>Errors of refraction</td>
<td>7 (1.8)</td>
</tr>
<tr>
<td>Eye hyperaemia</td>
<td>29 (7.4)</td>
</tr>
<tr>
<td>Eye pain</td>
<td>9 (2.3)</td>
</tr>
<tr>
<td>Increased intraocular pressure</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Iris pigmentation increased</td>
<td>6 (1.5)</td>
</tr>
<tr>
<td>Iris</td>
<td>-</td>
</tr>
<tr>
<td>Irritation eye</td>
<td>49 (12.4)</td>
</tr>
</tbody>
</table>
Keratitis | 4 (1.0) | 3 (0.7) | 1 (0.2)  
Oedema eyelid | 2 (0.5) | 4 (1.0) | 2 (0.5)  
Photophobia | 6 (1.5) | 1 (0.2) | 3 (0.7)  
Retinal disorder | 1 (0.3) | 3 (0.7) | 6 (1.4)  
Uveitis | 1 (0.3)* | - | -  
Vision abnormal | 26 (6.6) | 29 (7.0) | 22 (5.3)  
**Skin & Appendages**  
Hypertrichosis‡ | 9 (2.3) | 6 (1.4) | 2 (0.5)  
Pigmentation abnormal | 1 (0.3)* | - | -  
Seborrhoea | 2 (0.5) | 4 (1.0) | -  
Skin discoloration | 1 (0.3)* | - | -  
Skin disorder | 8 (2.0) | 4 (1.0) | -  
**Central & Peripheral Nervous System**  
Optic atrophy | 2 (0.5) | 3 (0.7) | 6 (1.4)  
Visual field defect | 18 (4.6) | 19 (4.6) | 18 (4.3)  
* Despite a low frequency of reports, some AEs are included in the listing due to the implication of a potentially sight-threatening condition.  
A patient is counted only once per preferred term.  
† Studies 004 and 005 included a 6 month and 053 a 12 month double-blinded period.  
‡ Includes darkening, lengthening and growing of eye lashes.

**Table 2**  
Systemic adverse events (AE) that occurred in ≥ 1% of patients*, in any of the treatment groups, by body system/preferred term†

<table>
<thead>
<tr>
<th>Body system / preferred term</th>
<th>Latanoprost/Timolol</th>
<th>Latanoprost N=394</th>
<th>Timolol N=415</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>3 (0.8)</td>
<td>4 (1.0)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Coughing</td>
<td>1 (0.3)*</td>
<td>-</td>
<td>2 (0.5)*</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>2 (0.5)*</td>
<td>2 (0.5)*</td>
<td>2 (0.5)*</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1 (0.3)</td>
<td>3 (0.7)</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>6 (1.5)</td>
<td>11 (2.7)</td>
<td>3 (0.7)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>24 (6.1)</td>
<td>18 (4.3)</td>
<td>22 (5.3)</td>
</tr>
<tr>
<td><strong>General</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>4 (1.0)</td>
<td>6 (1.4)</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>4 (1.0)</td>
<td>1 (0.2)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>Influenza-like symptoms</td>
<td>10 (2.5)</td>
<td>4 (1.0)</td>
<td>3 (0.7)</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>15 (3.8)</td>
<td>6 (1.4)</td>
<td>10 (2.4)</td>
</tr>
<tr>
<td>Hypertension aggravated</td>
<td>2 (0.5)*</td>
<td>1 (0.2)*</td>
<td>1 (0.2)*</td>
</tr>
<tr>
<td><strong>Metabolic &amp; Nutrition</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>5 (1.3)</td>
<td>2 (0.5)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Diabetes mellitus aggravated</td>
<td>-</td>
<td>1 (0.2)</td>
<td>-</td>
</tr>
<tr>
<td>Glycosuria</td>
<td>2 (0.5)</td>
<td>1 (0.2)</td>
<td>-</td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>1 (0.3)*</td>
<td>2 (0.5)*</td>
<td>2 (0.5)*</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>6 (1.5)</td>
<td>4 (1.0)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td><strong>Central &amp; Peripheral Nervous System</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (0.5)</td>
<td>4 (1.0)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Headache</td>
<td>9 (2.3)</td>
<td>15 (3.6)</td>
<td>5 (1.2)</td>
</tr>
<tr>
<td><strong>Musculo-Skeletal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>8 (2.0)</td>
<td>5 (1.2)</td>
<td>4 (1.0)</td>
</tr>
</tbody>
</table>
The following additional adverse events have been reported with latanoprost and timolol eye drops:

**Latanoprost**

**Ocular:** Foreign body sensation, punctate epithelial erosions, periorbital oedema, macular oedema (in aphakic, pseudophakic patients with torn posterior lens capsules or in patients with known risk factors for macular oedema), dry eye, corneal oedema and erosions, eyelash and vellus hair changes (increased length, thickness, pigmentation and number), misdirected eyelashes sometimes resulting in eye irritation and blurred vision, iris cyst, photophobia, periorbital and lid changes resulting in deepening of the eyelid sulcus.

**Respiratory, Thoracic and Mediastinal Disorders:** Asthma, asthma aggravation and acute asthma attacks.

**Skin and Subcutaneous Tissue Disorders:** Darkening of the palpebral skin of the eyelids and localised skin reaction on the eyelids.

**Musculoskeletal and Connective Tissue Disorders:** Muscle/joint pain.

**Cardiac Disorders:** Aggravation of angina in patients with pre-existing disease, palpitations

**General Disorders and Administration Site Conditions:** Non-specific chest pain.

**Infections and Infestations:** Herpetic keratitis

**Timolol**

**Special senses:** decreased corneal sensitivity and dry eyes, signs and symptoms of ocular irritation (e.g. burning, stinging, itching, tearing, redness), blepharitis, keratitis, vision blurred, dry eyes, corneal erosion, diplopia, ptosis, choroidal detachment (following filtration surgery) and tinnitus.

**Cardiovascular:** bradycardia, arrhythmia, atrioventricular block, hypotension, syncope, heart block, cerebrovascular accident, cerebral ischaemia, congestive heart failure, palpitation,
cardiac arrest, cardiac failure, oedema, claudication, Raynaud’s phenomenon, cold hands and feet and worsening of angina pectoris.

**Respiratory, Thoracic and Mediastinal Disorders:** bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, pulmonary oedema and nasal congestion.

**Body as a whole:** asthenia and fatigue.

**Skin and Subcutaneous Tissue Disorders:** alopecia, pseudopemphigoid, skin rash and psoriasiform rash or exacerbation of psoriasis.

**Hypersensitivity:** Signs and symptoms of allergic reactions including anaphylaxis, angioedema, urticaria, pruritus, localised and generalised rash.

**Nervous system/psychiatric:** nightmares, memory loss, increase in signs and symptoms of myasthenia gravis, paraesthesia, somnolence, headache, depression, behavioural changes and psychiatric disturbances including confusion, hallucinations, anxiety, disorientation and nervousness.

**Digestive:** nausea, diarrhoea, dry mouth, dysgeusia, vomiting, abdominal pain, and retroperitoneal fibrosis.

**Metabolism and Nutrition Disorders:** anorexia, masked symptoms of hypoglycaemia in diabetic patients.

**Musculoskeletal and Connective Tissue Disorders:** Myalgia

**Urogenital:** decreased libido, sexual dysfunction, Peyronie’s disease and impotence.

**Immunologic:** systemic lupus erythematosus.

**Post-Marketing Experience**
Cases of corneal calcification have been reported very rarely in association with the use of phosphate-containing eye drops in some patients with significantly damaged corneas.

**DOSAGE AND ADMINISTRATION**

**Adults (including the elderly)**
Recommended therapy is one eye drop in the affected eye(s) once daily. If one dose is missed, treatment should continue with the next dose as normal.

The use of Latanoprost/Timolol Sandoz 50/5 Eye Drops may be considered in patients who require both timolol and latanoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus latanoprost given once daily will be as well controlled with Latanoprost/Timolol Sandoz 50/5 Eye Drops given once daily. Latanoprost/Timolol Sandoz 50/5 Eye Drops should not be used to initiate therapy.

Latanoprost/Timolol Sandoz 50/5 Eye Drops should not be given more than once daily because latanoprost is most effective at this dosage. If there is inadequate response to
Latanoprost/Timolol Sandoz 50/5 Eye Drops, consideration should be given to using the individual agents with timolol dose twice daily.

If more than one topical ophthalmic drug is being used, the eye drop products should be administered at least 5 minutes apart.

Systemic absorption can be minimised by pressure on the tear duct immediately after application of the eye drop.

Use with contact lenses: The contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 minutes (see PRECAUTIONS).

OVERDOSAGE
Contact the Poisons Information Centre on 13 11 26 (Australia) for advice on management of overdose.

There is no human data available on overdosage with latanoprost and timolol eye drops.

There have been reports of inadvertent overdosage with timolol-maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, hypotension, bronchospasm, and cardiac arrest. Apart from ocular irritation and conjunctival or episcleral hyperaemia, the ocular effects of latanoprost administered at high doses are not known.

In case of overdose treatment should be supportive and symptomatic.

Studies have shown that timolol is not readily dialyzable. If Latanoprost/Timolol Sandoz 50/5 Eye Drops is accidentally ingested the following information may be useful: One bottle contains 125 µg latanoprost and 12.5 mg timolol. Both timolol and latanoprost are extensively metabolised in the liver. More than 90% of latanoprost is metabolised during the first pass through the liver. Intravenous infusion of up to 3 µg/kg in healthy volunteers induced no symptoms but a dose of 5.5-10 µg/kg caused nausea, abdominal pain, dizziness, fatigue, hot flushes and sweating. These events were mild to moderate in severity and resolved without treatment within 4 hours after terminating the infusion. In patients with bronchial asthma, bronchoconstriction was not induced by latanoprost when applied topically on the eyes in a dose of seven times the clinical dose of latanoprost.

PRESENTATION AND STORAGE CONDITIONS
Latanoprost/Timolol Sandoz 50/5 Eye Drops contain Latanoprost 50 µg/mL and Timolol 5 mg/mL in a 5 mL bottle (2.5 mL fill) with a dropper and screw cap. Each drop contains approximately 1.5 µg of latanoprost and 150 µg of timolol.

Store unopened bottle between 2 °C to 8 °C. Refrigerate do not freeze.

Store opened bottle below 25 °C in the carton. To be used within 4 weeks after opening. Protect from light.
NAME AND ADDRESS OF THE SPONSOR
Sandoz Pty Ltd
ABN 60 075 449 553
54 Waterloo Road
Macquarie Park, NSW 2113
Australia
Tel: 1800 634 500

POISON SCHEDULE OF THE MEDICINE
Schedule 4 – Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (the ARTG): 14/02/2014

DATE OF MOST RECENT AMENDMENT: 10/02/2016